Sanofi/GSK COVID Vaccine Hits Major Hurdle As It Fails To Work in Elderly Patients

Sanofi and GSK announced their experimental COVID vaccine candidate failed in some older patients.



French multinational pharmaceutical company Sanofi and Britain’s GSK announced on Friday their coronavirus vaccines will not be ready until the end of 2021. The announcement comes as the pharmaceutical industry leaders’ interim results showed their COVID vaccine had failed to produce a strong immune response in older adults.

Hours earlier it was reported that the Australian government has scrapped its homegrown COVID-19 vaccine after the inoculation produced false positive test results in several trial participants.

The announcements signal a major setback in the progress made so far to fight the coronavirus outbreak, which emerged in Wuhan, China last December and has killed over 1.5 million people worldwide.

Sanofi and GSK said the delay in their adjuvanted COVID-19 vaccine program was to improve immune response in the elderly. GSK had previously announced that it expected regulatory approvals in the first half of 2021. The vaccine’s availability has now been pushed back from mid-2021 to Q4 2021.

The world of vaccine development is fraught with possibilities for failure. Even the most optimistic analysts would not have expected pharmaceutical companies to develop a highly effective vaccine against a new virus in less than twelve months after its genome was sequenced.

The announcements that came today are a strong reminder of the difficulties of developing vaccines at breakneck speed.

COVID vaccine development Sanofi and GSK

Sanofi and GSK had previously announced that it expected regulatory approvals in the first half of 2021. The vaccine’s availability has now been pushed back from mid-2021 to Q4 2021.

COVID Vaccine Studies Postponed

The adjuvanted recombinant protein-based vaccine candidate, developed by Sanofi in partnership with GSK, is based on technology that Sanofi has used to produce seasonal influenza vaccines and on immunological agents developed by GSK. The companies planned to conduct further studies with an improved antigen formulation.

The European Union has ordered 300 million doses of the Sanofi/GSK coronavirus vaccine while the UK has asked for 60 million doses. Back home, the U.S. government has ordered an initial 100 million doses plus an option for 500 million.

COVAX, a global initiative aimed at speeding up the development, manufacture and equitable distribution of new vaccines, was to receive 200 million.

The pharmaceutical giants were disappointed by the hiccup.

Roger Connor, President of GSK Vaccines said: “The results of the study are not as we hoped. Based on previous experience and other collaborations, we are confident that GSK’s pandemic adjuvant system, when coupled with a COVID-19 antigen, can elicit a robust immune response with an acceptable reactogenicity profile. It is also clear that multiple vaccines will be needed to contain the pandemic. Our aim now is to work closely with our partner Sanofi to develop this vaccine, with an improved antigen formulation, for it to make a meaningful contribution to preventing COVID-19.”

Avatar
Christy Gren
Christy Gren is an Industry Specialist Reporter at Industry Leaders Magazine she enjoys writing about Unicorns, Silicon Valley, Startups, Business Leaders and Innovators. Her articles provide an insight about the Power Players in the field of Technology, Auto, Manufacturing, and F&B.

Recent Posts

Hyundai commits $7.4 billion in US investment by 2025

Hyundai commits $7.4 billion in US investment by 2025

South Korea’s Hyundai Motor Co., announced on Thursday it will soon start manufacturing electric vehicles in the United States. The automaker plans to produce EVs, upgrade produc
13 hours ago
US inflation report of 4.2 percent raises concerns

US inflation report of 4.2 percent raises concerns

The US reported the highest inflation recorded in the last dozen years at 4.2 percent in April, riding on government stimulus packages, improved energy prices, better spending and
16 hours ago
Aon – Willis asset disposal aims to ease approval of $30 billion merger

Aon – Willis asset disposal aims to ease approval of $30 billion merger

Aon Plc and Willis Towers Watson have agreed to sell $3.6 billion worth of assets to rival Arthur J. Gallagher & Co. in a bid to appease European competition regulators over th
2 days ago
Roblox declares Q1, reports $387 million revenue as bookings increase

Roblox declares Q1, reports $387 million revenue as bookings increase

Roblox, the hugely popular online gaming platform, reported its first-quarter earnings after becoming a listed company. Its revenue more than doubled as the videogame company benef
3 days ago
Weak US job report results in volatile market

Weak US job report results in volatile market

A weak job report resulted in a record close on Friday for the US stocks. The US labor department’s monthly non-farm payrolls report revealed employers hired 266,000 new workers
4 days ago
Star and Blackstone launch bids to buyout Australia’s Crown Resorts

Star and Blackstone launch bids to buyout Australia’s Crown Resorts

A bidding war has broken out between Australian casino company Star Entertainment Group and US private equity investor Blackstone Group over Crown Resorts, Australia’s bigges
4 days ago